Beatriz Barros-Santos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Beatriz Barros-Santos has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Joana Margarida Silva
Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, 4710-057 Braga, Portugal
3 shared publications - Carlos Campos-Marques
Life and Health Sciences Research Institute (ICVS), University of Minho
2 shared publications - Ioannis Sotiropoulos
Life and Health Sciences Research Institute (ICVS), University of Minho
2 shared publications - Rita Nóbrega-Martins
Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, 4710-057 Braga, Portugal
2 shared publications - Andreia Ferreira Salvador
Centre of Biological Engineering, University of Minho, Braga, Portugal
1 shared publication - Beatriz Escobar-Doncel
Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478 Lørenskog, Norway
1 shared publication
Latest Publications
- Open Access
- 1 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Brain Organoid and Systems Neuroscience Journal
- Vol. 3, 89-95
Integration of omics to explore novel disease pathways in Down Syndrome neurodegeneration – Focusing on integrated stress response
- 1 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Brain Organoid and Systems Neuroscience Journal
- Vol. 3, 89-95
Open AccessIntegration of omics to explore novel disease pathways in Down Syndrome neurodegeneration – Focusing on integrated stress response
- Open Access
- 7 November 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (45) , eady9811
NAD + reverses Alzheimer’s neurological deficits via regulating differential alternative RNA splicing of EVA1C
Dysfunctional alternative splicing events (ASEs) in RNA are markers of aging and Alzheimer’s disease (AD). As a key neuronal resilience metabolite, the oxidized nicotinamide adenine dinucleotide (NAD + ) slows down AD progression in preclinical studies with several clinical trials ongoing. However, the underlying molecular mechanisms around how NAD + enhances neuronal resilience, especially whether it has any effect on ASEs, have remained elusive. This study shows that NAD + augmentation corrects the ASEs of many genes via a key protein, EVA1C (epithelial V-like antigen 1 homolog C), which is involved in neuronal development and activities. EVA1C is reduced in the hippocampus in patients with AD compared to cognitively normal ones. NAD + -induced memory retention is partially dependent on EVA1C, as adeno-associated virus–based Eva1c knockdown in the hippocampal CA1 region annuls NAD + -induced memory improvement in pathological Tau–bearing mice. We propose that NAD + reduces AD pathologies, at least partially, via amplification of the NAD + - EVA1C splicing axis, pointing to a potential splice-switching therapy for AD.
- 7 November 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (45) , eady9811
Open AccessNAD + reverses Alzheimer’s neurological deficits via regulating differential alternative RNA splicing of EVA1C
Dysfunctional alternative splicing events (ASEs) in RNA are markers of aging and Alzheimer’s disease (AD). As a key neuronal resilience metabolite, the oxidized nicotinamide adenine dinucleotide (NAD + ) slows down AD progression in preclinical studies with several clinical trials ongoing. However, the underlying molecular mechanisms around how NAD + enhances neuronal resilience, especially whether it has any effect on ASEs, have remained elusive. This study shows that NAD + augmentation corrects the ASEs of many genes via a key protein, EVA1C (epithelial V-like antigen 1 homolog C), which is involved in neuronal development and activities. EVA1C is reduced in the hippocampus in patients with AD compared to cognitively normal ones. NAD + -induced memory retention is partially dependent on EVA1C, as adeno-associated virus–based Eva1c knockdown in the hippocampal CA1 region annuls NAD + -induced memory improvement in pathological Tau–bearing mice. We propose that NAD + reduces AD pathologies, at least partially, via amplification of the NAD + - EVA1C splicing axis, pointing to a potential splice-switching therapy for AD.
- Open Access
- 31 October 2025
- Published by Wiley in Journal of Neurochemistry
- Vol. 169 (11) , e70269
RNA Granules at the Crossroads of Synaptic Dysfunction and Neurodegeneration
RNA granules are dynamic, membraneless organelles essential for the spatial and temporal regulation of mRNA metabolism, particularly in neurons, where local protein synthesis supports synaptic plasticity and function. This review explores the diverse types of RNA granules (e.g., transport granules, stress granules, and processing bodies), their formation mechanisms, molecular composition, and relevance to synaptic physiology. We focus on the central role of RNA‐binding proteins (RBPs) in orchestrating granule dynamics and their fine‐tuning of synaptic responses under both physiological and stress conditions. Mounting evidence implicates the dysfunction of RNA granules in neurodegenerative diseases. Altered phase separation, RBP aggregation, and persistent stress granules contribute to the formation of pathological RNA granules that interfere with local translation and synaptic maintenance. Key RBPs, including TDP‐43, FUS, and TIA‐1, are frequently misregulated in disease contexts. Furthermore, Tau is a multifunctional protein traditionally associated with microtubule stabilization but is increasingly recognized for its role in the translational stress response, which includes RBP mislocalization and RNA granule disruption. We examine how chronic stress can exacerbate these mechanisms, acting as an environmental trigger of synaptic vulnerability associated with neurodegeneration. In summary, we explore a conceptual framework connecting RNA granule dysregulation, Tau pathology, and local translation disruption, three processes that converge on synaptic impairment, a central feature of many neurodegenerative diseases characterized by abnormal Tau. Investigating this triad presents a promising avenue for understanding disease mechanisms and identifying novel therapeutic targets that aim to restore RNA metabolism, prevent toxic Tau interactions, and preserve synaptic health. image
- 31 October 2025
- Published by Wiley in Journal of Neurochemistry
- Vol. 169 (11) , e70269
Open AccessRNA Granules at the Crossroads of Synaptic Dysfunction and Neurodegeneration
RNA granules are dynamic, membraneless organelles essential for the spatial and temporal regulation of mRNA metabolism, particularly in neurons, where local protein synthesis supports synaptic plasticity and function. This review explores the diverse types of RNA granules (e.g., transport granules, stress granules, and processing bodies), their formation mechanisms, molecular composition, and relevance to synaptic physiology. We focus on the central role of RNA‐binding proteins (RBPs) in orchestrating granule dynamics and their fine‐tuning of synaptic responses under both physiological and stress conditions. Mounting evidence implicates the dysfunction of RNA granules in neurodegenerative diseases. Altered phase separation, RBP aggregation, and persistent stress granules contribute to the formation of pathological RNA granules that interfere with local translation and synaptic maintenance. Key RBPs, including TDP‐43, FUS, and TIA‐1, are frequently misregulated in disease contexts. Furthermore, Tau is a multifunctional protein traditionally associated with microtubule stabilization but is increasingly recognized for its role in the translational stress response, which includes RBP mislocalization and RNA granule disruption. We examine how chronic stress can exacerbate these mechanisms, acting as an environmental trigger of synaptic vulnerability associated with neurodegeneration. In summary, we explore a conceptual framework connecting RNA granule dysregulation, Tau pathology, and local translation disruption, three processes that converge on synaptic impairment, a central feature of many neurodegenerative diseases characterized by abnormal Tau. Investigating this triad presents a promising avenue for understanding disease mechanisms and identifying novel therapeutic targets that aim to restore RNA metabolism, prevent toxic Tau interactions, and preserve synaptic health. image